PRICE T ROWE ASSOCIATES INC /MD/ - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.0%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$160
-46.5%
265,113
+15.4%
0.00%
Q2 2023$299
-24.7%
229,823
+2.1%
0.00%
Q1 2023$397
-21.1%
225,190
+40.6%
0.00%
Q4 2022$503
-99.9%
160,151
+3.2%
0.00%
Q3 2022$761,000
+25.6%
155,136
+6.0%
0.00%
Q2 2022$606,000
-25.8%
146,310
+4.1%
0.00%
Q1 2022$817,000
-21.1%
140,610
+1.8%
0.00%
Q4 2021$1,036,000
+29.7%
138,166
+55.7%
0.00%
Q3 2021$799,000
-18.5%
88,713
+8.4%
0.00%
Q2 2021$980,000
-12.5%
81,832
-8.4%
0.00%
Q1 2021$1,120,000
-49.0%
89,381
-36.5%
0.00%
Q4 2020$2,197,000
+47.7%
140,770
-10.6%
0.00%
Q3 2020$1,487,000
+5.5%
157,4030.0%0.00%
Q2 2020$1,410,000
+31.0%
157,403
-6.8%
0.00%
Q1 2020$1,076,000
+5.4%
168,969
+38.6%
0.00%
Q4 2019$1,021,000
-6.8%
121,948
+0.8%
0.00%
Q3 2019$1,095,000
-4.1%
120,996
+14.1%
0.00%
Q2 2019$1,142,000
+13.4%
106,068
+0.5%
0.00%
Q1 2019$1,007,000
-16.6%
105,569
+0.3%
0.00%
Q4 2018$1,208,000
-40.5%
105,269
-12.1%
0.00%
Q3 2018$2,030,000
+18.6%
119,793
-0.7%
0.00%
Q2 2018$1,712,000
+43.0%
120,595
+91.5%
0.00%
Q1 2018$1,197,000
+3.1%
62,983
-11.0%
0.00%
Q4 2017$1,161,000
+1.4%
70,800
-7.2%
0.00%
Q3 2017$1,145,000
+46.6%
76,300
-14.0%
0.00%
Q2 2017$781,000
+17.1%
88,700
-30.8%
0.00%
Q1 2017$667,000
+52.6%
128,200
-10.5%
0.00%
Q4 2016$437,000
-34.1%
143,2000.0%0.00%
Q3 2016$663,000
+16.3%
143,200
+45.4%
0.00%
Q2 2016$570,000
+16.8%
98,500
+22.2%
0.00%
Q1 2016$488,000
-15.1%
80,600
+27.9%
0.00%
Q4 2015$575,000
+47.1%
63,000
-9.2%
0.00%
Q3 2015$391,000
-43.3%
69,400
+11.8%
0.00%
Q2 2015$689,000
-12.3%
62,100
+24.0%
0.00%
Q1 2015$786,000
+9.9%
50,100
+6.6%
0.00%
Q4 2014$715,000
+41.0%
47,0000.0%0.00%
Q3 2014$507,000
-11.1%
47,000
+26.0%
0.00%
Q2 2014$570,000
-15.4%
37,3000.0%0.00%
Q1 2014$674,000
-25.8%
37,300
-43.0%
0.00%
Q4 2013$908,000
+117.7%
65,400
+64.3%
0.00%
Q3 2013$417,000
-33.0%
39,800
-50.0%
0.00%
Q2 2013$622,00079,6000.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Lombard Odier Asset Management (Switzerland) SA 1,539,994$11,550,0000.74%
Golden State Equity Partners 143,768$1,078,0000.54%
Rhenman & Partners Asset Management AB 765,000$5,975,0000.40%
WASATCH ADVISORS LP 10,960,982$82,207,0000.34%
KLK CAPITAL MANAGEMENT LLC 44,323$332,0000.32%
EMC Capital Management 61,394$460,0000.25%
Rokos Capital Management LLP 539,860$4,108,0000.25%
Long Focus Capital Management, LLC 245,000$1,838,0000.24%
Vanguard Capital Wealth Advisors 33,380$250,0000.18%
Fort Sheridan Advisors LLC 74,898$562,0000.16%
View complete list of SANGAMO THERAPEUTICS INC shareholders